{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:55:22Z","timestamp":1788479722939,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Densitometry"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jocd.2023.101453","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T11:47:11Z","timestamp":1700912831000},"page":"101453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hyperprolactinemia Due to Prolactinoma has an Adverse Impact on Bone Health with Predominant Impact on Trabecular Bone: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6865-5554","authenticated-orcid":false,"given":"Lakshmi","family":"Nagendra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-8805","authenticated-orcid":false,"given":"Deep","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunetra","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-2072","authenticated-orcid":false,"given":"Nitin","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3671-2312","authenticated-orcid":false,"given":"Ameya","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8458-9371","authenticated-orcid":false,"given":"Saptarshi","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocd.2023.101453_bib0001","first-page":"353","article-title":"Prevalence of macroprolactinemia in people detected to have hyperprolactinemia","volume":"13","author":"Sharma","year":"2021","journal-title":"J Lab Phys"},{"key":"10.1016\/j.jocd.2023.101453_bib0002","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s11102-020-01041-3","article-title":"Hyperprolactinemia and bone","volume":"23","author":"di Filippo","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.jocd.2023.101453_bib0003","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1210\/er.2018-00005","article-title":"Pituitary diseases and bone","volume":"39","author":"Mazziotti","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jocd.2023.101453_bib0004","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejim.2016.07.012","article-title":"Prevalence and predictors of hyperprolactinemia in subclinical hypothyroidism","volume":"35","author":"Sharma","year":"2016","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jocd.2023.101453_bib0005","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4274\/jcrpe.4536","article-title":"Hyperprolactinemia in children with subclinical hypothyroidism","volume":"9","author":"Sharma","year":"2017","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"10.1016\/j.jocd.2023.101453_bib0006","doi-asserted-by":"crossref","first-page":"333","DOI":"10.9758\/cpn.2019.17.3.333","article-title":"Serum prolactin and bone mineral density in schizophrenia: a systematic review","volume":"17","author":"Lally","year":"2019","journal-title":"Clin Psychopharmacol Neurosci Off Sci J Korean Coll Neuropsychopharmacol"},{"key":"10.1016\/j.jocd.2023.101453_bib0007","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00198-021-06289-4","article-title":"Bone microarchitecture impairment in prolactinoma patients assessed by HR-pQCT","volume":"33","author":"Wang","year":"2022","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"10.1016\/j.jocd.2023.101453_bib0008","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11102-011-0293-4","article-title":"High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas","volume":"14","author":"Mazziotti","year":"2011","journal-title":"Pituitary"},{"key":"10.1016\/j.jocd.2023.101453_bib0009","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11102-007-0064-4","article-title":"Bone density in women with prolactinoma treated with dopamine agonists","volume":"11","author":"Naliato EC","year":"2008","journal-title":"Pituitary"},{"key":"10.1016\/j.jocd.2023.101453_bib0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1365-2265.2000.00902.x","article-title":"Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization","volume":"52","author":"Colao","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jocd.2023.101453_bib0011","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jocd.2023.101453_bib0012","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3803\/EnM.2020.818","article-title":"Efficacy and safety of the novel dipeptidyl peptidase-4 inhibitor gemigliptin in the management of Type 2 diabetes: A meta-analysis","volume":"36","author":"Dutta","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.jocd.2023.101453_bib0013","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jocd.2023.101453_bib0014","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"21","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jocd.2023.101453_bib0015","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/jbmr.5650100512","article-title":"Plasma levels of parathyroid hormone-related peptide are elevated in hyperprolactinemia and correlated to bone density status","volume":"10","author":"Stiegler","year":"1995","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101453_bib0016","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3109\/09513591003686320","article-title":"The influence of other than prolactin hormones on bone mineral density in women with hyperprolactinaemia of various origins","volume":"26","author":"Bolanowski","year":"2010","journal-title":"Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol"},{"key":"10.1016\/j.jocd.2023.101453_bib0017","first-page":"423","article-title":"Plasma calcitonin, IGF-I levels and vertebral bone mineral density in hyperprolactinemic women during bromocriptine treatment","volume":"128","author":"T\u00f8rring","year":"1993","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.jocd.2023.101453_bib0018","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1210\/jcem-59-6-1050","article-title":"Vertebral body bone mineral content in hyperprolactinemic women","volume":"59","author":"Koppelman","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jocd.2023.101453_bib0019","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23f14790","article-title":"Prolactin-raising and prolactin-sparing antipsychotic drugs and the risk of fracture and fragility fracture in patients with schizophrenia, dementia, and other disorders","volume":"84","author":"Andrade","year":"2023","journal-title":"J Clin Psychiatry"},{"issue":"47","key":"10.1016\/j.jocd.2023.101453_bib0020","doi-asserted-by":"crossref","first-page":"e1967","DOI":"10.1097\/MD.0000000000001967","article-title":"bone mineral density in schizophrenia: an update of current meta-analysis and literature review under guideline of prisma","volume":"94","author":"Tseng","year":"2015","journal-title":"Med (Baltimore)"},{"key":"10.1016\/j.jocd.2023.101453_bib0021","first-page":"745","article-title":"Osteoporotic fractures in patients with untreated hyperprolactinemia vs. those taking dopamine agonists: A systematic review and meta-analysis","volume":"36","author":"D'Sylva","year":"2015","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.jocd.2023.101453_bib0022","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality\u2013the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101453_bib0023","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1210\/jcem-67-1-124","article-title":"Effects of prolactin and estrogen deficiency in amenorrheic bone loss","volume":"67","author":"Klibanski","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2023.101453_bib0024","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-104-6-777","article-title":"Osteoporosis in men with hyperprolactinemic hypogonadism","volume":"104","author":"Greenspan","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocd.2023.101453_bib0025","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.bone.2007.11.008","article-title":"Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand\/osteoprotegerin ratio","volume":"42","author":"Seriwatanachai","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2023.101453_bib0026","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/jcb.22161","article-title":"Evidence for direct effects of prolactin on human osteoblasts:inhibition of cell growth and mineralization","volume":"107","author":"Seriwatanachai","year":"2009","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.jocd.2023.101453_bib0027","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Clinical Densitometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695023001038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695023001038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:45:31Z","timestamp":1761083131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094695023001038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1094695023001038"],"URL":"https:\/\/doi.org\/10.1016\/j.jocd.2023.101453","relation":{},"ISSN":["1094-6950"],"issn-type":[{"value":"1094-6950","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperprolactinemia Due to Prolactinoma has an Adverse Impact on Bone Health with Predominant Impact on Trabecular Bone: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Densitometry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocd.2023.101453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The International Society for Clinical Densitometry. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101453"}}